Primary vitreoretinal lymphoma
Clinical trials for Primary vitreoretinal lymphoma explained in plain language.
Never miss a new study
Get alerted when new Primary vitreoretinal lymphoma trials appear
Sign up with your email to follow new studies for Primary vitreoretinal lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Triple-Drug attack stop eye lymphoma in its tracks?
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can i…
Matched conditions: PRIMARY VITREORETINAL LYMPHOMA
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New eye injection shows promise for rare eye cancer
Disease control Recruiting nowThis study tests an eye injection of ADX-2191 (a form of methotrexate) in 20 adults with primary vitreoretinal lymphoma, a rare eye cancer. The goal is to see if it safely clears cancer cells from the eye. Participants receive injections at different frequencies over 8 weeks.
Matched conditions: PRIMARY VITREORETINAL LYMPHOMA
Phase 3 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC